Study Information

Title: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma External
Status: Recruiting participants
Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma,; Mycosis Fungoides; Cutaneous T-Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Methotrexate or Bexarotene
Health Topics: Non-Hodgkin Lymphoma

Contact Information